Hypoglycemia Fear Survey (HFS)
Also known as: HFS, HFS-II
The Hypoglycemia Fear Survey (HFS) is a self-report measure that quantifies fear of, anxiety about, and behavioral responses to hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Originally developed by Cox and colleagues in 1987 and revised (HFS-II) in 1993, the HFS captures the emotional and behavioral impact of hypoglycemia risk, particularly the tendency to run higher blood glucose to avoid episodes, making it essential for understanding a major barrier to optimal glucose control in insulin-dependent diabetes.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The HFS is recommended for all patients with type 1 diabetes on insulin and type 2 diabetes on insulin, particularly those with: (1) history of severe hypoglycemia with impaired awareness (inability to recognize symptoms early), (2) reluctance to increase insulin doses or use intensive regimens due to hypoglycemia fear, (3) HbA1c above target despite apparently good adherence (suggesting intentional high glucose avoidance), (4) anxiety symptoms centered on hypoglycemia, (5) recurrent hypoglycemic episodes with minimal symptoms (hypoglycemia unawareness), and (6) consideration for continuous glucose monitoring (CGM) or insulin pump therapy (assessment of readiness and fear as barrier). HFS is less relevant for non-insulin diabetic patients.
Strengths & limitations
- Hypoglycemia-specific: HFS directly measures fear and anxiety unique to hypoglycemia risk, capturing a critical barrier to optimal control that generic anxiety measures miss.
- Bidimensional: separate Worry and Behavior subscales permit identification of anxious vs. avoidant phenotypes, enabling targeted intervention (cognitive therapy for worry, behavioral problem-solving for avoidant behavior).
- Validated across type 1 and insulin-treated type 2 diabetes: extensive normative data in diverse insulin-dependent populations.
- Responsive to intervention: HFS scores improve following behavioral therapy, continuous glucose monitoring introduction, or insulin pump therapy; useful outcome for research.
- Clinically actionable: elevated HFS identifies a modifiable barrier and guides intervention (psychosocial support, technology adoption) alongside medication adjustment.
- Does not measure actual hypoglycemia risk or frequency: HFS quantifies fear and response to fear, not actual hypoglycemic episodes; a patient with high HFS may actually have low hypoglycemia frequency (overestimated risk).
- Moderate overlap with general anxiety: HFS-Worry subscale correlates with anxiety symptoms; elevated HFS may reflect generalized anxiety disorder rather than hypoglycemia-specific fear.
- Does not directly measure glucose control: while high HFS may correlate with higher HbA1c (due to protective high glucose running), HFS is not a glucose control measure; clinical outcomes require concurrent HbA1c measurement.
- Recall bias: HFS items ask about typical experiences and behaviors, which may be influenced by recent hypoglycemic episodes or current emotional state.
- Cultural variation: most validation data are from English-speaking, high-income populations; expression of fear and avoidance may differ across cultures.
Frequently asked
What HFS scores indicate need for intervention?
HFS-II subscale means >3.0 (on 1–5 scale) or total HFS-II >120 warrant structured intervention. Options include: (1) behavioral therapy (cognitive reframing, exposure therapy for fear), (2) continuous glucose monitoring (reduces hypoglycemia frequency and unpredictability, lowering fear), (3) insulin pump therapy (enables better micro-dosing, reducing hypoglycemia risk), or (4) diabetes education focused on hypoglycemia recognition and management. Moderate elevation (means 2.0–3.0) may benefit from educational support without formal psychotherapy.
Does continuous glucose monitoring reduce HFS scores?
Yes, studies show that CGM introduction is associated with reduced HFS scores (especially Behavior subscale) as real-time glucose visibility and predictive alarms reduce unexpected hypoglycemia. CGM combined with behavioral support (diabetes educator, counselor) shows greatest HFS reduction. However, some patients with very high baseline HFS may need concurrent psychosocial intervention (therapy) for full benefit.
How do I distinguish hypoglycemia fear from general anxiety disorder?
Administer both HFS and GAD-7. HFS >3.0 with GAD-7 <10 suggests specific hypoglycemia fear amenable to diabetes-specific intervention (CGM, education, diabetes-focused therapy). HFS >3.0 with GAD-7 ≥10 suggests comorbid anxiety disorder requiring mental health evaluation and possible antidepressant consideration alongside diabetes-specific support. Both require intervention but the targets differ.
Is elevated HFS always problematic?
Moderate HFS (means 2.0–3.0) reflects appropriate caution about hypoglycemia and may drive good safety behaviors (carrying glucose, checking frequently). Very high HFS (>3.0) or HFS-Behavior >3.5 becomes problematic if it causes intentional glucose overrunning (HbA1c >8.0%) or activity restriction. The goal is to enable people with diabetes to maintain reasonable glucose targets while managing hypoglycemia risk—not to eliminate all fear but to prevent fear from sabotaging control.
Can I use HFS in type 2 diabetes on oral medications only?
HFS is designed for insulin-treated diabetes. Type 2 patients on insulin may have elevated HFS if their insulin dose is substantial; those on oral medications or GLP-1 agonists alone have minimal hypoglycemia risk and HFS is not indicated. If screening type 2 patients, clarify insulin dose first; if on basal insulin or more, HFS may be appropriate.
Sources
- Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, G. (1987). Fear of hypoglycemia: Quantification, validation, and utilization. Diabetes Care, 10(5), 617–621. DOI: 10.2337/diacare.10.5.617 ↗
- Cox, D. J., Ritterband, L. M., Hessler, D., Polis, S., Sinha, A., & Gonder-Frederick, L. (2007). Accuracy of perceived blood glucose in adults with type 1 diabetes. Diabetes Care, 30(3), 529–535. link ↗
How to cite this page
ScholarGate. (2026, June 3). Hypoglycemia Fear Survey (HFS). ScholarGate. https://scholargate.app/en/cardiology/hypoglycemia-fear-survey
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Diabetes Distress ScaleCardiology↔ compare
- Diabetes Self-Efficacy ScaleCardiology↔ compare
- Problem Areas in Diabetes ScaleCardiology↔ compare